HEMOPHILIA ISN’T HIS SUPERPOWER,
BUT SOME DAYS IT FEELS PRETTY CLOSE

HEMOPHILIA ISN’T HIS SUPERPOWER, BUT SOME DAYS IT FEELS PRETTY CLOSE

We give you the facts. Where you take them is up to you.

5

Days

Extended Dosing

It’s the only FACTOR VIII with the potential for extended dosing intervals—up to every 5 days.

0

Spontaneous
Bleeds and
Joint Bleeds

Proven Protection*

In one of the largest Hemophilia A studies, prophy patients had a median of 0 spontaneous bleeds and 0 joint bleeds.

2K

Patients

Experience

More than 2,000 patients
have chosen ELOCTATE
in the US since 2014.

The recommended starting regimen is 50 IU/kg every 4 days as directed by your doctor. In children under 6 years of age, the recommended starting regimen is 50 IU/kg administered twice weekly. The regimen can be adjusted based on your body’s individual response.

Talk to your doctor to see if ELOCTATE is right for you.

‡ Median of 1.6 overall bleeds per year. 0 bleeds in 45% of adults and adolescents.

* ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

† Data on file. Waltham, MA; Bioverativ Therapeutics Incorporated.

5-DAY DOSING LETS YOU DO YOU

5-DAY DOSING
LETS YOU DO YOU

ELOCTATE is the only Factor VIII that offers extended protection up to every 5 days.

With dosing schedules that are adjusted to your individual needs, ELOCTATE offers the potential for fewer infusions.

*ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.

FC FUSION:

A natural pathway
to extended protection

FC FUSION:

A natural pathway to
extended protection

While some proteins are broken down very quickly, we believe that Fc Fusion allows ELOCTATE to use your body's natural pathway to recycle and recirculate in the bloodstream longer and offer extended protection.

I went from infusing about 182 times a year with ADVATE® to infusing 91 times a year with ELOCTATE. And I'm working with my doctor to get to 73 infusions a year.

Note: This is a personal account of an ELOCTATE Peer. Please talk to your healthcare provider about whether ELOCTATE may be right for you. Individual results may vary.

There’s nothing quite like Eloctate

In clinical studies, ELOCTATE was shown to last 50% longer in the body than ADVATE®.1

ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire Plc.

1 ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] Package Insert. Page 12. 2017.

TAKE A LOOK AT OUR NUMBERS:
BLEED Rates and CONTROL

Adults

(12 years and older)

Children

(Under 12 years old)

Protection against bleeds when you need it most

Take a look at the results of one of the largest clinical trials in the tratment of Hemophilia A, representing over 34,500 patient exposure days: 116 adults and adolescents on prophy experienced median bleed rates of zero spontaneous bleeds and zero joint bleeds.

Tab Image 1

Bleed control when you need control

Of those who experienced a bleed:

Tab Image 2
  • 98% of those bleeds where controlled with 1 or 2 infusions (n=740)

  • 100% of those bleeds where controlled with 2 or more infusions (n=757)

On-demand treatment and control of bleeding episodes

+

Can we get a high five?

In adults (n=28), after single dose of 50 IU/kg. Mean days = 5.10 95% Confidence Interval = 4.54, 5.66.

Can we get a high five?

ELOCTATE helped adult patients maintain blood clotting factor levels above 1% for an average of 5 days in the clinical study.

And five days is super important. That’s because 1% is the minimum threshold recommended by the Medical and Scientific Advisory Council (MASAC).*

*Guidelines of the National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC #241) recommend that prophylactic therapy should be instituted early (prior to the onset of frequent bleeding), with the aim of keeping the trough FVIII level above 1% between doses.

In adults (n=28), after single dose of 50 IU/kg. Mean days = 5.10 95% Confidence Interval = 4.54, 5.66.

Wait! There’s more to
learn about ELOCTATE.

indications and important facts about eloctate 

what is the most important information I should know about ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]? You should not use ELOCTATE if you are allergic to ELOCTATE or any of its other ingredients. Tell your healthcare provider if you have had an allergic reaction to any Factor VIII product prior to using ELOCTATE.
Allergic reactions may occur. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash or hives.

Your body can also make antibodies called "inhibitors" against ELOCTATE. This can stop ELOCTATE from working properly. Your healthcare provider may give you blood tests to check for inhibitors.


THE MOST COMMON SIDE EFFECTS OF ELOCTATE INCLUDE: headache, rash, joint pain, muscle pain and general discomfort. These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider for more information and about any side effect that bothers you or does not go away.


WHAT SHOULD I TELL MY HEALTHCARE PROVIDER BEFORE STARTING ELOCTATE?

Tell your healthcare provider about all your health conditions, including if you:

  • Have or have had any medical problems.
  • Are taking any prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal medicines.
  • Are pregnant or planning to become pregnant. It is not known if ELOCTATE may harm your unborn baby.
  • Are breastfeeding. It is not known if ELOCTATE passes into breast milk or if it can harm your baby.

AFTER STARTING ELOCTATE:

If your bleeding is not controlled and you experience a lack of clinical response to Factor VIII therapy, call your healthcare provider right away.

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ELOCTATE for a condition for which it was not prescribed. Do not share ELOCTATE with other people, even if they have the same symptoms that you have.


ELOCTATE INDICATIONS

ELOCTATE is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency).

Your healthcare provider may give you ELOCTATE when you have surgery.


HOW SHOULD I RECEIVE ELOCTATE?

ELOCTATE should be administered as ordered by your healthcare provider. You should be trained on how to do infusions by your healthcare provider. Many people with hemophilia A learn to infuse ELOCTATE by themselves or with the help of a family member. See the booklet called "Instructions for Use" packaged in your ELOCTATE for directions on infusing. If you are unsure of the procedure, please ask your healthcare provider.


IMPORTANT FACTS ABOUT ELOCTATE

Please read this information carefully before using ELOCTATE and each time you get a refill, as there may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.


QUESTIONS?

The risk information provided here is not comprehensive. To learn more, talk about ELOCTATE with your healthcare provider or pharmacist.
The FDA-approved product labeling can be found at www.eloctate.com or 1-855-MyELOCTATE (693-5628). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.


MANUFACTURED BY

Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


Please see Full Prescribing Information

Questions?

1-855-MYELOCTATE (1-855-693-5628)

Monday-Friday, 8am-8pm, EST

BIVV logo

©2017 Bioverativ. All rights reserved.

ELO logo

ELO-US-1631

Questions?

1-855-MYELOCTATE (1-855-693-5628)

Monday-Friday, 8am-8pm, EST